CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
September 16th 2016
Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.
August 22nd 2016
After a long lapse in advancements for bladder cancer, the approval of Tecentriq is changing the field.
August 17th 2016
Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.
August 13th 2016
Randy F. Sweis talks to CURE about the future of treatment for GU cancers.
July 20th 2016
CURE spoke with Stanley Yap about how physicians can improve care for patients with muscle-invasive bladder cancer.
July 19th 2016
The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.
July 7th 2016
“Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo,” said Jean Viallet.
June 23rd 2016
A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.
June 15th 2016
A recent phase 1 study shows promise for the treatment of bladder cancer.
June 6th 2016
Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.
May 19th 2016
Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.
May 18th 2016
Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.
May 13th 2016
The approval of atezolizumab will change the treatment paradigm of bladder cancer overnight, says Robert Dreicer.
May 9th 2016
Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.
April 21st 2016
Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.
April 1st 2016
The FDA's breakthrough designation is meant to expedite the development of therapies that offer substantial benefits over existing options.
January 26th 2016
"Response rate and survival were similar to historical controls, and the primary endpoint was not met," said lead investigator Matthew Galsky.
November 18th 2015
The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.
October 20th 2015
The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:
September 24th 2015
The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.
July 25th 2015
Rick Bulifant shares his bladder cancer story.
May 27th 2015
CURE Magazine and the Bladder Cancer Advocacy Network (BCAN), whose mission is to advance research, provide information and support, and raise awareness of bladder cancer, have joined forces to battle the fifth most common type of cancer, which begins when the cells in the bladder's lining start to grow out of control.
May 20th 2015
Data from an ongoing trial showed that one fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor Keytruda.
April 18th 2015
Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.
March 13th 2013
In the right cancer, radiation and chemotherapy can make a powerful duo.
December 17th 2012
Urinary incontinence after a cancer diagnosis can be managed.
March 14th 2012
New treatments for bladder cancer may be nearing the finish line.
March 14th 2012
Editor Debu Tripathy, MD, highlights the need for new treatments needed for bladder cancer and other stories in CURE.